Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
3.090
+0.090 (3.00%)
Dec 3, 2025, 4:00 PM EST - Market closed
Atea Pharmaceuticals Employees
Atea Pharmaceuticals had 56 employees as of December 31, 2024. The number of employees decreased by 19 or -25.33% compared to the previous year.
Employees
56
Change (1Y)
-19
Growth (1Y)
-25.33%
Revenue / Employee
n/a
Profits / Employee
-$2,625,446
Market Cap
241.41M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56 | -19 | -25.33% |
| Dec 31, 2023 | 75 | 5 | 7.14% |
| Dec 31, 2022 | 70 | 11 | 18.64% |
| Dec 31, 2021 | 59 | 20 | 51.28% |
| Dec 31, 2020 | 39 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AVIR News
- 14 days ago - Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 20 days ago - Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript - Seeking Alpha
- 21 days ago - Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 26 days ago - Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 - GlobeNewsWire
- 4 weeks ago - Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025 - GlobeNewsWire
- 6 weeks ago - Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025 - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 - GlobeNewsWire